Table 2.
Diagnoses of the patients evaluated using telemedicine
| Endocrine condition | n (%) | The count of communications to the endocrine illness ratio | Specific diagnosis | n | Number of communications | Procedure |
|---|---|---|---|---|---|---|
| Diabetes | 96 (36%) | 2.76 |
Type 1 DM—multiple-dose regimen Type 1 DM—insulin pump treatment Type 2 DM Neonatal DM MODY |
75 14 3 2 2 |
189 49 8 4 15 |
Glucose monitoring, adjusting insulin dose as required (target range 70–180 mg/dL) |
| Thyroid disease | 56 (20.9%) | 1.82 |
Congenital hypothyroidism Hashimoto thyroiditis Hyperthyroidism High TSH (neonatal screening) Drug-induced hypothyroidism Thyroid nodules Central hypothyroidism |
32 12 4 3 2 2 1 |
56 15 20 5 3 2 1 |
Test results were evaluated, drug doses were adjusted. Screening patients were started on treatment, and follow-up was planned or discharged |
| Pubertal disorders | 32 (12%) | 1.43 |
Presumptive precocious puberty Precocious puberty on treatment Functional amenorrhea Abnormal uterine bleeding Polycystic ovary (PCOS) |
17 12 1 1 1 |
21 20 1 1 3 |
Patients with presumptive precocious puberty were evaluated, and Tanner staging was performed. Patients on treatment were followed, and therapy was continued. The menstrual cycle was followed |
| Pituitary disorder |
28 (10.5%) |
2.57 |
Isolated growth hormone (GH) deficiency Panhypopituitarism Prolactinoma Partial empty sella Septo-optic dysplasia Germ cell tumor- panhypopituitarism- DI Diabetes insipidus (DI) |
19 4 1 1 1 1 1 |
34 10 1 1 2 22 2 |
Continuity of treatment was supported. The growth velocity of patients on GH treatment was monitored, and side effects were questioned. Patients with DI were monitored clinically and with electrolyte measurement |
| Adrenal disorder | 19 (7.1%) | 1.89 |
Presumptive congenital adrenal hyperplasia Classical congenital adrenal hyperplasia Familial glucocorticoid resistance |
9 9 1 |
10 25 1 |
Clinical and laboratory follow-up was performed |
| Normal variant short stature | 10 (3.7%) | 1.1 |
Familial short stature Constitutional growth delay |
6 4 |
6 5 |
The growth velocity was monitored |
| Disorder of sexual development | 8 (3%) | 1.25 |
Disorder of sexual development Turner syndrome |
5 3 |
6 3 |
Treatment was continued. The growth velocity of those on GH were monitored and side effects were questioned |
| Obesity | 8 (3%) | 1 | - | 8 | 8 | Weight and height were followed. Exercise and diet programs were provided |
| Metabolic bone disease | 5 (1.9%) | 2.8 |
Osteogenesis imperfecta Vitamin D-dependent rickets type 1 Achondroplasia Osteoporosis |
2 1 1 1 |
6 1 3 4 |
Continuity of treatment was supported |
| Hyperinsulinism | 5 (1.9%) | 9 |
Transient congenital hyperinsulinism Persistent congenital hyperinsulinism |
2 3 |
7 38 |
Glucose monitoring and continuity of treatment was supported. Side effects were questioned |
| Total | 267 (100%) | 2.27 | 267 | 608 |